Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEX:MEDP 93 Operating Margin % is 20.76% as of Jun. 2026, which is 18% above its 10-year median of 17.63. GuruFocus rates MEX:MEDP with a GF Score™ of 93/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 88.18% on this metric.
Medpace Holdings Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Medpace Holdings's Operating Margin % or its related term are showing as below:
MEX:MEDP'
s Operating Margin % Range Over the Past 10 Years
Min: 12.45 Med: 17.63 Max: 21.19
Current: 20.97
MEX:MEDP's Operating Margin % is ranked better than 88.18% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.35
vs MEX:MEDP: 20.97
Medpace Holdings's 5-Year Average Operating Margin % Growth Rate was 3.80% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Medpace Holdings Operating Margin % Related Terms
Medpace Holdings Operating Margin % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MEDP vs ICLR, RVTY, CRL: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Medpace Holdings's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a Operating Margin % of 20.76% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Medpace Holdings and its competitors. This is 18% above median its historical median of 17.63. Over the past decade, Medpace Holdings' Operating Margin % has ranged from 12.45 to 21.19. According to the industry distribution chart, Medpace Holdings ranks #24 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 11.8%.
Is Medpace Holdings' Operating Margin % too high?
Medpace Holdings' current Operating Margin % of 20.76% is 18% above median its 10-year median of 17.63. Over the past 10 years, this metric has ranged from a low of 12.45 to a high of 21.19. Based on the distribution chart, Medpace Holdings ranks #24 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Operating Margin % compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #24 out of 203 companies for Operating Margin %. This places Medpace Holdings in the top 12% of its industry — outperforming the majority of peers. Historically, Medpace Holdings' own Operating Margin % has ranged from 12.45 to 21.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Operating Margin % is 20.76%, which is 18% above median its own 10-year median of 17.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current Operating Margin % of 20.76%. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current Operating Margin % is 20.76%, which is 18% above median its 10-year median of 17.63. Medpace Holdings' overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current Operating Margin % is 20.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
Operating Margin %: 20.76% (18% above median its 10-year median of 17.63)
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
93GF Score
Get the complete analysis for MEX:MEDP
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
